PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer

被引：0
|
作者：
Xiangyu Qiu
Zhaoan Yu
Xiaoqing Lu
Xin Jin
Jinrong Zhu
Rongxin Zhang
机构：
[1] GuangdongProvincialKeyLaboratoryofAdvancedDrugDelivery,GuangdongProvincialEngineeringCenterofTopicalPreciseDrugDeliverySystem,SchoolofLifeSciencesandBiopharmaceutics,GuangdongPharmaceuticalUniversity
来源：
Cancer Biology & Medicine | 2024年 / 21卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R730.5 [肿瘤治疗学];
学科分类号：
摘要：
<正>The emergence of tumor immunotherapy represents a pivotal milestone in cancer treatment, heralding new hope for cancer patients globally. Immune checkpoint inhibitors have been instrumental in this advance, playing a crucial role in modulating the immune system response to neoplasms. Specifically, the therapies targeting the programmed death 1/programmed cell death ligand 1（PD-1/PD-L1） immune checkpoint pathways have shown significant efficacy in treating various cancers1.
引用
收藏
页码：970 / 976
页数：7
相关论文
共 50 条
  • [41] The therapeutic potential of PD-1/PD-L1 blockade in smoking exposed emphysema
    Kim, Jiseon
    Kim, Na Hyun
    Shon, Chang-Ho
    Huh, Jin-Young
    Han, Kyung Yeon
    Kim, Kyu-Tae
    Shin, Sun Hye
    Park, Hye Yun
    Lee, Sei Won
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [42] Enrichment of LAG-3, but not PD-1, on Double Negative T Cells at the Female Genital Tract
    Juno, Jennifer A.
    Lajoie, Julie
    Stalker, Andrew T.
    Oyugi, Julius
    Kimani, Makobu
    Kimani, Joshua
    Plummer, Francis A.
    Fowke, Keith R.
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2014, 72 (06) : 534 - 540
  • [43] PD-1 and LAG-3 immune checkpoints constitutive activators exhibit differential expression phenotypes
    Chocarro, L.
    Palmeiro, E. B.
    Arasanz, H.
    Bocanegra, A.
    Zuazo, M.
    Echaide, M.
    Morente, P.
    Fernandez-Rubio, L.
    Fernandez-Hinojal, G.
    Garnica, M.
    Ramos, P.
    Garcia-Granda, M. J.
    Vera, R.
    Kochan, G.
    Escors, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S365 - S366
  • [44] REVIEW Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
    Ge, Yanjun
    Zhang, Yuchen
    Zhao, Kong-Nan
    Zhu, Haiyan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 3055 - 3070
  • [45] Mechanisms of Resistance to PD-1 Checkpoint Blockade
    Justin C. Moser
    Siwen Hu-Lieskovan
    Drugs, 2020, 80 : 459 - 465
  • [46] Mechanisms of Resistance to PD-1 Checkpoint Blockade
    Moser, Justin C.
    Hu-Lieskovan, Siwen
    DRUGS, 2020, 80 (05) : 459 - 465
  • [47] Cancer immunotherapy by PD-1 blockade
    Honjo, Tasuku
    CANCER SCIENCE, 2018, 109 : 197 - 197
  • [48] PD-1 blockade therapy for cancer
    Ribas, Antoni
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10)
  • [49] Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumors
    Morgado, Micaela
    Datar, Ila
    Wang, Jun
    Sanmamed, Miguel F.
    McEachern, Kristen
    Jenkins, David
    Chen, Lieping
    Carvajal-Hausdorf, Daniel
    Rimm, David L.
    Herbst, Roy S.
    Schalper, Kurt A.
    CANCER RESEARCH, 2018, 78 (13)
  • [50] PD-1 BLOCKADE IN CANCER IMMUNOTHERAPY
    Srivastava, N.
    Avigan, D.
    Rosenblatt, J.
    DRUGS OF THE FUTURE, 2014, 39 (02) : 129 - 132
12345